Key Points
- Director Johannes Gerardus Chri Schikan sold 800 Pharvaris shares at an average price of $36.19, generating $28,952 and reducing his ownership by 0.69% to 115,167 shares. He had also sold 200,000 shares for $7 million on September 17.
- Pharvaris shares opened at $32.99, with a market capitalization of about $2.16 billion and a 12-month range of $20.65 to $43.25.
- Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $59.87, though the company remains loss-making after reporting an $0.81 quarterly loss per share versus $0.75 expected.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Johannes Gerardus Chri Schikan sold 800 shares of the stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $36.19, for a total transaction of $28,952.00. Following the sale, the director directly owned 115,167 shares in the company, valued at approximately $4,167,893.73. The trade was a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Johannes Gerardus Chri Schikan also recently made the following trade(s):
- On Thursday, September 17th, Johannes Gerardus Chri Schikan sold 200,000 shares of Pharvaris stock. The stock was sold at an average price of $35.00, for a total value of $7,000,000.00.
- On Tuesday, June 30th, Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88.
- On Monday, June 29th, Johannes Gerardus Chri Schikan sold 6,888 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total value of $241,424.40.
Pharvaris Price Performance
Pharvaris stock opened at $32.99 on Friday. The stock has a market capitalization of $2.16 billion, a PE ratio of -10.82 and a beta of -2.33. The business has a 50 day simple moving average of $35.35 and a 200-day simple moving average of $31.98. Pharvaris N.V. has a 12 month low of $20.65 and a 12 month high of $43.25.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). On average, equities research analysts anticipate that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.
Institutional Trading of Pharvaris
Several large investors have recently bought and sold shares of PHVS. venBio Partners LLC purchased a new position in Pharvaris in the 2nd quarter worth approximately $160,569,809. Wellington Management Group LLP boosted its stake in Pharvaris by 12.9% during the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company's stock worth $82,748,000 after buying an additional 274,034 shares during the last quarter. Commodore Capital LP boosted its stake in Pharvaris by 1.6% during the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company's stock worth $54,211,000 after buying an additional 29,525 shares during the last quarter. 5AM Venture Management LLC purchased a new stake in Pharvaris in the 2nd quarter valued at $27,581,008. Finally, Seven Fleet Capital Management LP grew its holdings in Pharvaris by 144.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company's stock valued at $26,782,000 after buying an additional 457,804 shares in the last quarter.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on PHVS shares. Cantor Fitzgerald reissued an "overweight" rating and set a $65.00 target price on shares of Pharvaris in a research note on Monday, September 14th. Royal Bank Of Canada lifted their price objective on Pharvaris from $52.00 to $62.00 and gave the stock an "outperform" rating in a report on Wednesday, September 9th. New Street Research set a $60.00 target price on Pharvaris in a research report on Friday, August 14th. Guggenheim lifted their price target on Pharvaris from $40.00 to $44.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. Finally, Rosenblatt Securities set a $60.00 price target on Pharvaris in a research report on Wednesday, September 9th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $59.87.
Check Out Our Latest Report on Pharvaris
Key Stories Impacting Pharvaris
Here are the key news stories impacting Pharvaris this week:
- Positive Sentiment: Analyst sentiment remains supportive: Wells Fargo, Cantor Fitzgerald, Leerink Partners and Citizens JMP maintain positive ratings, with several raising price targets to $65–$79. The consensus rating is “Moderate Buy,” with an average target of $59.87. Pharvaris analyst ratings and insider trading report
- Positive Sentiment: Institutional ownership trends were favorable, including a new approximately $160.6 million position by venBio Partners, a 12.9% increase by Wellington Management and a 144.6% increase by Seven Fleet Capital. These purchases may signal confidence in Pharvaris’ oral hereditary angioedema treatment platform.
- Neutral Sentiment: Reported short interest was listed at zero shares as of September 24, implying no days-to-cover and little evidence of meaningful short-selling pressure. However, the figure may reflect a reporting or data anomaly given the company’s trading volume.
- Negative Sentiment: Several executives sold shares. CFO David Nassif sold 6,000 shares for approximately $218,820, while Director Johannes Gerardus Chri Schikan sold 800 shares in a separate filing. Additional reports cited sales of 200,000 shares by Schikan, 52,500 by Elisabeth Bjork and 100,000 by Peng Lu. The cluster of insider selling could weigh on sentiment, although executives retained sizable holdings. Pharvaris insider selling report
- Negative Sentiment: Pharvaris remains loss-making and recently reported a quarterly loss of $0.81 per share, wider than the $0.75 analyst estimate. Analysts expect a full-year loss of approximately $3.12 per share, leaving the stock dependent on clinical and regulatory progress for further upside.
About Pharvaris
(
Get Free Report)
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.
Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
